Therapeutic Efficacy Models - Antibacterial
UNTHSC Pre-Clinical Services currently offers the following protocols. Additional protocols can be developed and validated to meet the individual requirements of the sponsor.
Mouse Acute Lethal Infection (septicemia)
ED50 determinations for experimental molecules against infections with both gram-positive and gram-negative pathogens.
Mouse Subcutaneous Abscess
A chronic skin infection model involving either Staphylococcal (MRSA / MRSE), Streptococcal (pyogenes) or Pseudomonas aeruginosa isolates.
Mouse Superficial Skin Infection Model
A superficial skin infection model for the assessment of topical applications involving either Staphylococcus aureus or Streptococcus pyogenes infections.
Mouse Biofilm Catheter Implant
Model of device-related biofilm infection using subcutaneous S. aureus infected implants.
Mouse Lung Infection
Murine lung infection by S. pneumoniae, K. pneumoniae and P. aeruginosa with survival or CFU as measured endpoints.
Rat Central Venous Catheter Infection
Biofilm-like infection with S. aureus of an intravascular indwelling jugular catheter.
Granuloma Pouch
Infected pouch model for the simultaneous determination of penetration (levels) and efficacy (CFU counts) of administered agents in the rat or mouse.
Helicobacter pylori Gastritis (mouse)
Gastric infection model using H. pylori SS1 strain with efficacy measured as CFU log reduction / relapse.
Hamster C. difficile Infection
Experimental CDAD model for the evaluation of survival / relapse, GI pharmacokinetics and Tox A/B detection.
Neutropenic Thigh Infection Model
Determination of the Pharmacokinetic / Pharmacodynamic indices as related to the efficacy of an antimicrobial agent.
Additional Protocols / Procedures
Protocols of interest can be developed for sponsor as required.
In Development
Mouse urinary tract infection (UTI), intra-abdominal abscess, HCDAD with BI/NAP1 isolate, Acinetobacter lung infection.